This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Amano, H Articles by Hashimoto, H Search for Related Content PubMed PubMed Citation Articles by Amano, H Articles by Hashimoto, H Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CYCLOPHOSPHAMIDE PREDNISOLONE Medline Plus Health Information Lupus Social Bookmarking                         What's this?

Effect of intravenous cyclophosphamide in systemic lupus erythematosus: relation to lymphocyte subsets and activation markers

Department of Rheumatology and Internal Medicine, Juntendo University, School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113, Japan

S Morimoto

H Kaneko

Y Tokano

Y Takasaki

H Hashimoto

Department of Rheumatology and Internal Medicine, Juntendo University, Tokyo, Japan

Since the mechanism mediating the beneficial effect of intravenous cyclophosphamide (IVCY) in systemic lupus erythematosus (SLE) is unknown, we investigated lymphocyte subsets and markers of activated lymphocytes in patients received IVCY, and compared the results with the effect of steroid pulse. In 55 patients with SLE, 34 patients receiving IVCY [21 cases (61.8%) were responsive] and 25 patients received steroid pulse [21 cases (84.0%) were responsive] (four patients who were resistant to steroid pulse therapy were transferred to IVCY). When the lymphocyte subsets and markers of activated lymphocytes were compared in the responsive and unresponsive group of IVCY, soluble CD4 levels and the ratio of HLA-DP-positive T cells were significantly higher in the unresponsive group. Further, the changes of these markers and costimulatory molecules [LFA-1 (CD11a), ICAM-1 (CD54), CD40 and CD40-ligand (CD154)] were also examined in the responsive patients. The ratio of HLA-DP-positive T cells did not change in the IVCY-responsive group, while it decreased in the steroid pulse therapy-responsive group. The ratio of CD11a on T cells increased and CD54 on B cells decreased in the IVCY-responsive group. The ratio of CD154 on T cells increased in the steroid pulse-responsive group, while it decreased in the IVCY-responsive group. These results suggest that the effect of IVCY is different to that of steroid pulse therapy and mainly related to B cell activation, and that these markers may contribute to predict the responsiveness of IVCY.

Key Words: activated lymphocytes • costimulatory molecules • intravenou scyclophosphamide • systemic lupus erythematosus

Lupus, Vol. 9, No. 1, 26-32 (2000)
DOI: 10.1177/096120330000900106


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C B Driver, M Ishimori, and M H Weisman The B cell in systemic lupus erythaematosus: a rational target for more effective therapy Ann Rheum Dis, October 1, 2008; 67(10): 1374 - 1381. [Abstract] [Full Text] [PDF]

				E Toubi and A Kessel Intravenous cyclophosphamide in SLE Lupus, July 1, 2000; 9(6): 478 - 478. [PDF]